ReviewApplied microbiology and biotechnology2005
Microbiological control in stem cell banks: approaches to standardisation.
Review in Applied microbiology and biotechnology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Metagenomic-driven predictive biosafety and contamination traceability in stem cell manufacturing: Translating outbreak genomics into regenerative medicine.Regenerative therapy · 2026Review
- Contamination rates in umbilical cord Mesenchymal stromal cell cryopreservation: a report from Vinmec tissue bank.Cell and tissue banking · 2026Article
- Improving rigor and reproducibility through implementation of the ISSCR standards for human stem cell use in research.Stem cell reports · 2026Article
- Standard Methods for Quality Control in Cell-Based Medicinal Products and their Validation for Clinical Applications.Advanced biomedical research · 2026Review
- Microbiological risk assessment during the procurement and processing of cells, tissues and breast milk using the MiRCA tool.Scientific reports · 2025Article
- Establishment & characterization of a non-adherent insect cell line for cultivated meat.Scientific reports · 2025Article
- Advancements in theFrontiers in toxicology · 2025Review
- Impact of COVID-19 pandemic on cord blood banking and transplantation.Cell and tissue banking · 2024Review
- Reducing Microbial Contamination in Hematopoietic Stem Cell Products and Quality Improvement Strategy: Retrospective Analysis of 1996-2021 Data.Annals of laboratory medicine · 2023Article
- Cultured Meat Safety Research Priorities: Regulatory and Governmental Perspectives.Foods (Basel, Switzerland) · 2023Article
- Establishment of a keratinocyte and fibroblast bank for clinical applications in Japan.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2023Article
- Bioreactor Parameters for Microcarrier-Based Human MSC Expansion under Xeno-Free Conditions in a Vertical-Wheel System.Bioengineering (Basel, Switzerland) · 2020Article
- The quality evaluation system establishment of mesenchymal stromal cells for cell-based therapy products.Stem cell research & therapy · 2020Article
- Production of biomedical cell products: requirements for the quality of donor material and excipients of animal origin (review).RSC medicinal chemistry · 2020Review
- Generation of pancreatic β cells for treatment of diabetes: advances and challenges.Stem cell research & therapy · 2018Review
- A review of the emerging potential therapy for neurological disorders: human embryonic stem cell therapy.American journal of stem cells · 2017Review
- Propagation of Human Embryonic Stem Cells on Human Amniotic Fluid Cells as Feeder Cells in Xeno-Free Culture Conditions.Development & reproduction · 2016Article
- Mesenchymal Stem Cells as Therapeutics Agents: Quality and Environmental Regulatory Aspects.Stem cells international · 2016Review
- Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use.Stem cells and development · 2014Article
- Culture bag systems for clinical applications of adult human neural crest-derived stem cells.Stem cell research & therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transplant of cells of human origin is an increasingly complex sector of medicine which entails great opportunities for the treatment of a range of diseases. Stem cell banks should assure the quality, traceability and safety of cultures for transplantation and must implement an effective programme to prevent contamination of the final product. In donors, the presence of infectious micro-organisms, like human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T cell lymphotrophic virus, should be evaluated in addition to the possibility of other new infectious agents (e.g. transmissible spongiform encephalopathies and severe acute respiratory syndrome). The introduction of the nucleic acid amplification can avoid the window period of these viral infections. Contamination from the laboratory environment can be achieved by routine screening for bacteria, fungi, yeast and mycoplasma by European pharmacopoeia tests. Fastidious micro-organisms, and an adventitious or endogenous virus, is a well-known fact that will also have to be considered for processes involving in vitro culture of stem cells. It is also a standard part of current good practice in stem cell banks to carry out routine environmental microbiological monitoring of the cleanrooms where the cell cultures and their products are prepared. The risk of viral contamination from products of animal origin, like bovine serum and mouse fibroblasts as a "feeder layer" for the development of embryonic cell lines, should also be considered. Stem cell lines should be tested for prion particles and a virus of animal origin that assure an acceptable quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.